The global orthobiologics market size was valued at USD 5.0 billion in 2015 and is expected to witness a CAGR of 7.5% during the forecast period. The industry is primarily driven by the increasing number of orthopedic procedures globally as a consequence of an upsurge in accidents and obesity. The rising geriatric population base, highly susceptible to spinal and other orthopedic disorders are also contributing to the rising number of orthopedic procedures.
Orthobiologics market, by product, 2014 - 2025 (USD Billion)
According to a study presented at the American Academy of Orthopedic Surgeons in 2006, hip and knee replacements are anticipated to raise upto 174% and 673% respectively, in the next 20 years. This unprecedented growth in orthopedic procedures exemplifies the highly probable demand for orthobiologics to curb the above mentioned over the coming years.
Furthermore, rising R&D investments and collaborations by prominent medical device and biotechnology companies, leading to the advent of advanced orthobiologics is presumed to widen the base for growth of orthobiologics. For instance, in May 2015, Bone Biologics Corp., is in its development stages of bone growth stimulator orthobiological product Nell-1, in collaboration with the University of California. This subsequent rise in R&D efforts led to the expansion of a range of pipeline products that is expected to provide this vertical with lucrative growth opportunities in the future.
In the product segment, viscosupplementation held the dominant share of orthobiologics market in 2015. The substantial share is attributed to the high adoption of these products as a consequence of wide range availability and unprecedented adoption in diseases such as osteoarthritis, hip degenerative joint disease.
The high adoption rate is presumed to be a consequence of the benefits associated with viscosupplementation. These benefits include better knee movement, pain reduction, less-invasive, and fewer side effects. It is also presumed to be a result of high demand for minimally invasive operative procedures leading to high acceptance by the patient population base.
In 2015, spinal fusion accounted for a majority share of over 50.0% in the application segment. The dominant share can be attributed to the consistent penetration of demineralized bone matrices, bone morphogenetic proteins, autografts and allografts in spinal fusion surgeries owing to its ability to provide high bone stability and rapid bone healing thereby improving long-term spinal disorders.
Orthobiologics application market by application, 2015 & 2025 (USD Billion)
Other benefits of orthobiological products in spinal fusion, such as rapid stimulation of cells to initiate bone formation, reduced hospital stay duration, and visits, are believed to be responsible for garnering a larger share in the application segment. The substantial share attained by orthobiologics is also believed to be a consequence of the presence of third-party insurers and reimbursement available for fusion enhancement products thus triggering growth.
In 2015, hospitals held a dominant share in the end-use segment. Increasing adoption of orthobiological products in a wide range of spinal and reconstructive surgeries performed in hospitals is a key factor attributed to the segment share dominance. Moreover, specialized patient care and easy availability of a wide range of orthobiologics in hospitals are anticipated to be a segment growth factor.
In addition, high patient turnaround, frequent readmissions, and large procedure volumes contributed toward the segment share. Moreover, the supportive infrastructure facilitates accurate operative procedures, which is further anticipated to raise the growth potential.
North America held a substantial share of the global market in 2015. The share acquired by this region can be attributed to the presence of the majority of the prominent players involved in promoting quality care and undertaking new product development strategies. In addition, reimbursement policies available for soft tissue healing and fusion enhancement products are also significantly contributing toward the regional share.
Orthobiologics market share by region, 2015 (%)
The Asia Pacific regional space is expected to grow at an exponential rate throughout the forecast period. This growth is mainly due to the rising healthcare spending and disposable income and physician awareness levels pertaining to the benefits of these products.
In addition, the heightening quality of healthcare infrastructure is further anticipated to present the market with lucrative growth opportunities across this region. Moreover, increasing product launch across this region aside from growing competition among the key industry players is also one of the significant factors contributing toward the growth.
For instance, in January 2016, Bioventus launched DUROLANE, hyaluronic acid-based single-injection for joint-fluid osteoarthritis treatment, in Taiwan. This product launch led to a greater geographical presence of the company and also fueled the product penetration of orthobiological products in Asia Pacific region.
Key participants of orthobiologics market include Medtronic, Smith & Nephew plc, Stryker Corporation, DePuy Synthes, Inc., and Genzyme. The aforementioned companies are extensively incorporating new product development activities, collaborations and distribution enhancement strategies, mergers & acquisitions as well as frequent product approval.
For instance, in May 2016, NuVasive Inc. from the U.S. launched next-generation biologics technology, AttraX Putty. It is a synthetic bone graft, indicated in posterolateral spinal surgery, as an autograft extender. This product launch was carried out to expand the product portfolio and gain a competitive advantage over other market players.
Market size value in 2020
USD 5.46 billion
Revenue forecast in 2025
USD 10.2 billion
CAGR of 7.5% from 2016 to 2025
Base year for estimation
2014 - 2015
2016 - 2025
Revenue in USD million and CAGR from 2016 to 2025
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Product, application, end-use, region
North America; Europe; Asia Pacific; Latin America; MEA
U.S.; Canada; UK; Germany; China; Japan; India; Brazil; Mexico; South Africa
Key companies profiled
Bone Biologics, Corp.; Medtronic; Bioventus LLC; Pioneer Surgical Technology; Smith & Nephew plc; Stryker Corporation; DePuy Synthes, Inc.; Genzyme; Osiris Therapeutics, Inc.; Globus Medical; Wright Medical Technology; Orthofix, Inc.; NuVasive, Inc.; Zimmer Biomet; Anthrex
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
This report forecasts revenue growth and provides an analysis on the industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the orthobiologics market on the basis of product, application, end-use, and region:
Global Orthobiologics Product Outlook (Revenue, USD Billion, 2014 - 2025)
Demineralized Bone Matrix(DBM)
Bone Morphogenetic Protein (BMP)
Synthetic Bone Substitutes
Stem Cell Therapy
Global Orthobiologics Application Outlook (Revenue, USD Billion, 2014 - 2025)
Global Orthobiologics End-use Outlook (Revenue, USD Billion, 2014 - 2025)
Orthobiologics Regional Outlook (Revenue, USD Billion, 2014 - 2025)
Middle East and Africa
b. The global orthobiologics market size was estimated at USD 5.16 billion in 2019 and is expected to reach USD 5.46 billion in 2020.
b. The global orthobiologics market is expected to grow at a compound annual growth rate of 6.2% from 2019 to 2026 to reach USD 7.75 billion by 2027.
b. North America dominated the orthobiologics market with a share of 47.76% in 2019. This is attributable to presence of majority of the prominent players involved in promoting quality care and undertaking new product development strategies.
b. Some key players operating in the orthobiologics market include Bone Biologics, Corp., Medtronic, Bioventus LLC, Pioneer Surgical Technology, Smith & Nephew plc, Stryker Corporation, DePuy Synthes, Inc., Genzyme, Osiris Therapeutics, Inc., Globus Medical, Wright Medical Technology, Orthofix, Inc., NuVasive, Inc., Zimmer Biomet, and Anthrex.
b. Key factors that are driving the market growth increasing number of orthopedic procedures globally as a consequence of an upsurge in accidents and obesity and rising geriatric population base.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
"The quality of research they have done for us has been excellent."